Multi-Gene Edited Anti-CD19 CAR-T Cells for Enhanced Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapy faces challenges in improving T cell persistence in culture, which affects manufacturing and clinical applications, particularly in achieving long-term durability and reducing immunosuppressive effects in the tumor microenvironment.
Innovation Solution
Genetically engineered anti-CD19 CAR-T cells with disruptions in the Regnase 1 (Reg1), Transforming Growth Factor Beta Receptor II (TGFBRII), and beta-2 microglobulin (β2M) genes, using CRISPR/Cas-mediated gene editing, are developed to enhance expansion and persistence, reducing immunosuppression and improving therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional CAR-T cell therapy is used, then initial anti-tumor activity is achieved, but T cell persistence in culture is limited
Solution Approach 1:
The patent applies parameter changes by disrupting multiple genes (Regnase 1, TGFBRII, TRAC, β2M) in CAR-T cells to alter their biological parameters. Specifically, Regnase 1 disruption increases mRNA stability and protein half-life, TGFBRII disruption reduces immunosuppression, TRAC disruption prevents graft-versus-host disease, and β2M disruption reduces host-versus-graft response. These parameter changes enable prolonged T cell persistence and enhanced therapeutic durability.
Solution Approach 2:
The patent creates a composite genetic modification approach by combining multiple gene disruptions (Regnase 1, TGFBRII, TRAC, β2M) within a single CAR-T cell population. This composite approach synergistically enhances T cell persistence, reduces immunosuppression, prevents autoimmune reactions, and improves overall therapeutic durability beyond what single-gene edits could achieve.
2Reliability
If T cell persistence is improved through gene disruption, then therapeutic efficacy is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-disrupting multiple genes (Regnase 1, TGFBRII, TRAC, β2M) in donor T cells before CAR transduction and infusion. This preliminary genetic modification is performed in a standardized pipeline using CRISPR/Cas9 or other gene editing technologies, allowing the complex multi-gene disruption to be achieved through established manufacturing protocols rather than ad-hoc approaches.
Solution Approach 2:
The patent uses copying by creating standardized gene disruption templates and using them across multiple CAR-T cell manufacturing batches. The same CRISPR guide RNAs and editing protocols can be replicated to consistently disrupt the same genes (Regnase 1, TGFBRII, TRAC, β2M) in different donor T cell populations, ensuring manufacturing consistency despite the complexity of multi-gene editing.
3Reliability
If multiple genes are disrupted to enhance CAR-T cell function, then antitumor activity increases, but risk of off-target effects increases
Solution Approach 1:
The patent applies local quality by precisely targeting specific genes (Regnase 1, TGFBRII, TRAC, β2M) for disruption using CRISPR guide RNAs designed to affect only these specific loci. Each guide RNA is optimized to bind selectively to its target sequence, ensuring that the gene disruptions occur at the intended locations without causing off-target effects in other genomic regions.
Solution Approach 2:
The patent converts potential harm from multi-gene disruption into benefit by carefully selecting which genes to disrupt. The disruption of Regnase 1, TGFBRII, TRAC, and β2M, while increasing manufacturing complexity, produces CAR-T cells with enhanced persistence, reduced immunosuppression, and improved safety profiles that ultimately increase antitumor efficacy and reduce off-target harmful effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The genetically modified CAR-T cells exhibit increased expansion and functional persistence, leading to enhanced therapeutic efficacy against CD19+ cancers, with synergistic effects observed in animal models, allowing for effective treatment at lower doses and prolonged antitumor activity.
Implementation Method 1
The CARs may be introduced into the T cells using CRISPR/Cas9 gene editing technology
Implementation Method 2
the disruption of both the Reg1 gene and the TGFBRII gene showed synertistic effect in increasing CAR-T cell expansion and functional persistence
Implementation Method 3
the receptors enable the T cells to kill cancer cells
Implementation Method 4
When these allogeneic CAR T cells are injected into a patient, the receptors enable the T cells to kill cancer cells
Data Source
AI summary
Genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting CD19 and having multiple genetic edits, including a disrupted TRAC gene, a disrupted β2M gene, a disrupted Regnase 1 gene, and/or a disrupted TGFBRII gene. Also provided herein are methods of making such genetically engineered T cells and methods of using the genetically engineered T cells in cancer treatment.